Business
PAOG Announces New Engagement To Prepare For Investigational New Drug Application With FDA
PAOG Announces New Engagement To Prepare For Investigational New Drug Application With FDA.
About this update from Pao Group, Inc.
[{"type":"text","content":"\n\n\n\nPAOG Announces New Engagement To Prepare For Investigational New Drug Application With FDA\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nPAOG Announces New Engagement To Prepare For Investigational New Drug Application With FDA\nPR Newswire\nSANDUSKY, Ohio, Oct. 1, 2020\n\n\n\nSANDUSKY, Ohio, Oct. 1, 2020 /PRNewswire/ -- PAO Group, Inc. (USOTC: PAOG) today announced engaging Saul Kaye the founder of iCAN (www.israel-cannabis.com) and CannaTech (www.canna-tech.co) to provide an independent review of PAOG's RespRx research for the treatment of Chronic Obstructive Pulmonary Disease (COPD), and to help prepare RexpRx for engaging with a contract research organization (CRO) to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA).\nSaul is a licensed pharmacist and a serial entrepreneur with both retail and e-commerce experience. He has founded multiple companies spanning six countries across the US, Europe, Israel and Australia.\nSaul Kaye is a global influencer in the medical cannabis industry, a widely respected speaker on cannabis industry movements and has been engaged in the past by other notable cannabis industry participants including Alvit, Canopy Growth, Altria and many other global cannabis companies.\nOn July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).  RespRx is a cannabis treatment under development for COPD derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled \"METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.\" \nIn an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis. \nWith RespRx now in house, PAOG has engaged multiple new experts from both the university and commercial medical research community to evaluate...